Abstract： The treatment of multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) is prone to more time-consuming, complex, toxic and ineffective. MDR-TB has low treatment success rate (52%) and high fatality rate (17%), as well as high rate of lost visits(15%), while the treatment success rate of XDR-TB is only 26%. It’s urgent to develop new drugs and chemotherapy regimens to improve the efficacy for MDR/XDR-TB. Delamanid (Dlm) has a strong killing effect on Mycobacterium tuberculosis (MTB) in vitro and in vivo. When MDR-TB patients are treated with optimized background regimen containing Dlm, the two-month sputum negative conversion rate is increased, case fatality is decreased and the prognosis is improved. This article reviews the progress on characteristics, in vitro activity, animal tests, clinical efficacy and safety of Dlm.